MarketPeel
Insider Trading Intelligence
Pricing
…
SB

Scott L. Burrows

SYRE
CHIEF FINANCIAL OFFICER · SPYRE THERAPEUTICS, INC. · CIK 0001853327
FILING MIX · LIFETIME37%/63%
BUYS
17
SELLS
29
TOTAL VALUE
$5.75M
COMPANIES
2
ACTIVE SINCE
Apr 2021
HOLDINGS NOW
164,609
AVG SELL PX
$47.50
TRADE KIND
SHOWING 46 / 46
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
14 backtested trades · 8 horizons · 19 pending
Forward-return performance of every backtestable P/S trade by Scott L. Burrows, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d14+35.71%-1.53%-0.25%-1.28%+3.13%—
14d14+50.00%+0.96%+1.51%-0.56%-3.38%—
30d14+35.71%+5.78%+2.78%+2.99%+4.69%—
60d14+21.43%+26.88%+1.70%+21.27%+21.62%—
90d14(1 pending)+30.77%+24.07%+4.32%+8.96%+22.98%—
180d14(5 pending)+44.44%+15.27%+1.71%+13.56%+19.59%—
1y14(6 pending)+100.00%-22.84%+8.96%-31.79%-32.96%—
2y14(7 pending)+85.71%-32.94%+32.32%-65.25%-63.17%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
SYRE · 105,494 shares · as of Jul 1, 2026
0100,589201,179301,768402,357202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
2026
FLOW · 17 buys / 29 sellsCOVERAGE · 22 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
SYRE
SPYRE THERAPEUTICS, INC.
SALE
Chief Financial Officer
7,500——352,357Jul 1, 2026Jul 2, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
5,775$87.55$505.6K99,719Jul 1, 2026Jul 2, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
7,500$14.50$108.8K105,494Jul 1, 2026Jul 2, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,725$88.37$152.4K97,994Jul 1, 2026Jul 2, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE
Chief Financial Officer
10,000$87.14$871.4K97,994Jun 25, 2026Jun 26, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE
Chief Financial Officer
15,000——359,857Jun 25, 2026Jun 26, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE
Chief Financial Officer
5,000$87.12$435.6K107,994Jun 25, 2026Jun 26, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
15,000$14.50$217.5K112,994Jun 25, 2026Jun 26, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE
Chief Financial Officer
7,500——374,857Jun 1, 2026Jun 3, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
3,100$72.06$223.4K97,994Jun 1, 2026Jun 3, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
7,500$14.50$108.8K105,494Jun 1, 2026Jun 3, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,801$69.75$125.6K103,693Jun 1, 2026Jun 3, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,599$70.77$183.9K101,094Jun 1, 2026Jun 3, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE
Chief Financial Officer
12,500——382,357May 1, 2026May 1, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
12,500$14.50$181.3K110,494May 1, 2026May 1, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
12,500$71.37$892.1K97,994May 1, 2026May 1, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,300$49.98$65.0K97,994Apr 1, 2026Apr 3, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
7,500$14.50$108.8K105,494Apr 1, 2026Apr 3, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE
Chief Financial Officer
7,500——394,857Apr 1, 2026Apr 3, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
6,200$49.21$305.1K99,294Apr 1, 2026Apr 3, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE
Chief Financial Officer
2,500——402,357Mar 3, 2026Mar 3, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
200$41.66$8.3K97,994Mar 3, 2026Mar 3, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,300$40.56$93.3K98,194Mar 3, 2026Mar 3, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
2,500$14.50$36.3K100,494Mar 3, 2026Mar 3, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
140,000——140,000Jan 9, 2026Jan 13, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE
Chief Financial Officer
18,428$16.26$299.6K97,994Sep 2, 2025Sep 3, 2024 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
95,500——95,500Jan 15, 2025Jan 17, 2025 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE
Chief Financial Officer
18,531$28.17$522.1K116,422Sep 3, 2024Sep 5, 2024 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
70,000——70,000Feb 1, 2024Feb 2, 2024 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
134,953——134,953Dec 22, 2023Dec 22, 2023 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
Chief Financial Officer
291$15.26$4.4K59,115Mar 6, 2023Mar 8, 2023 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
Chief Financial Officer
18$16.52$29738,406Mar 2, 2023Mar 2, 2023 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
55,800——55,800Mar 2, 2023Mar 6, 2023 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
21,000——59,406Mar 2, 2023Mar 6, 2023 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
Chief Financial Officer
1,416$15.82$22.4K38,424Mar 2, 2023Mar 2, 2023 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
Chief Financial Officer
416$16.17$6.7K39,840Feb 28, 2023Mar 2, 2023 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
Chief Financial Officer
5,000——37,277Sep 16, 2022Sep 20, 2022 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
5,000$1.68$8.4K40,256Sep 16, 2022Sep 20, 2022 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
Chief Financial Officer
10$16.44$16435,256Mar 7, 2022Mar 7, 2022 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
Chief Financial Officer
293$16.86$4.9K35,266Mar 4, 2022Mar 7, 2022 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
35,300——35,300Mar 3, 2022Mar 7, 2022 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
13,300——35,559Mar 3, 2022Mar 7, 2022 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
Chief Financial Officer
420$17.75$7.5K22,259Mar 1, 2022Mar 3, 2022 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
55,704——55,704Dec 30, 2021Jan 4, 2022 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
Chief Financial Officer
12,560$20.07$252.1K22,679Dec 27, 2021Dec 28, 2021 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
23,000——23,000Apr 1, 2021Apr 5, 2021 ↗View →
Other insiders · SYRE
Loading peer insiders…
About this filer
CIK 0001853327
ROLE
Chief Financial Officer
PRIMARY
SYRE
COMPANIES
2
ACTIVE SINCE
Apr 2021
MARKETPEEL · /INSIDER/0001853327DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback